These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 31243506)
21. The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review. Gonzalez-Horta A Nat Prod Commun; 2015 Oct; 10(10):1775-8. PubMed ID: 26669123 [TBL] [Abstract][Full Text] [Related]
22. Personalized Medicine Approaches in Parkinson's Disease: The Genetic Perspective. Gasser T J Parkinsons Dis; 2016 Oct; 6(4):699-701. PubMed ID: 27662328 [TBL] [Abstract][Full Text] [Related]
23. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088 [TBL] [Abstract][Full Text] [Related]
25. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease. Doria M; Maugest L; Moreau T; Lizard G; Vejux A Free Radic Biol Med; 2016 Dec; 101():393-400. PubMed ID: 27836779 [TBL] [Abstract][Full Text] [Related]
26. Can the disease course in Parkinson's disease be slowed? Korczyn AD; Hassin-Baer S BMC Med; 2015 Dec; 13():295. PubMed ID: 26653056 [TBL] [Abstract][Full Text] [Related]
27. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. Sardi SP; Cedarbaum JM; Brundin P Mov Disord; 2018 May; 33(5):684-696. PubMed ID: 29704272 [TBL] [Abstract][Full Text] [Related]
28. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Rocha EM; De Miranda B; Sanders LH Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134 [TBL] [Abstract][Full Text] [Related]
29. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262 [TBL] [Abstract][Full Text] [Related]
30. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432 [TBL] [Abstract][Full Text] [Related]
31. Role of rodent models in advancing precision medicine for Parkinson's disease. Simons E; Fleming SM Handb Clin Neurol; 2023; 193():3-16. PubMed ID: 36803818 [TBL] [Abstract][Full Text] [Related]